IO Biotech appointed Marjan Shamsaei, PharmD as the new SVP

Dr. Shamsaei brings a wealth of expertise in developing commercial and portfolio strategies across various therapeutic areas

IO Biotech, a clinical-stage biopharmaceutical company specializing in developing innovative cancer vaccines leveraging its T-win platform, has announced the appointment of Marjan Shamsaei, PharmD, as Senior Vice President of Commercial Development and Portfolio Lead for IO102-IO103, the company's primary cancer vaccine candidate currently undergoing a pivotal Phase 3 trial. Ms. Shamsaei will join the company's executive team, reporting directly to IO Biotech CEO Mai-Britt Zocca, Ph.D., and will be based in the United States. Dr. Zocca expressed enthusiasm about Ms. Shamsaei's extensive experience in oncology product commercialization and growth strategy, highlighting its significance as IO Biotech progresses toward commercial readiness for IO102-IO103.

Dr. Shamsaei, in turn, conveyed her excitement about joining IO Biotech during this period of growth, emphasizing her commitment to advancing novel cancer therapeutics and addressing the ongoing need for improved treatment options. With over 25 years of experience in the pharmaceutical and biotechnology industry, Dr. Shamsaei brings a wealth of expertise in developing commercial and portfolio strategies across various therapeutic areas. Prior to joining IO Biotech, she held key leadership positions at companies including Allogene Therapeutics, Five Prime Therapeutics (acquired by Amgen), Genentech, Jazz Pharmaceuticals, and SUGEN/Pharmacia (acquired by Pfizer). Dr. Shamsaei holds a Doctorate in Pharmacy from the University of California, San Francisco, and a Bachelor of Arts in Chemistry from the University of Colorado.